Clinical patterns and seasonal trends in respiratory syncytial virus hospitalizations in São Paulo, Brazil

Respiratory syncytial virus epidemics: the ups and downs of a seasonal virus

Respiratory syncytial virus (RSV) is the most common pathogen causing lower respiratory tract infections in infants worldwide. Lower respiratory tract infections caused by RSV occur epidemically, and the appearance of epidemics seems to vary with latitude, altitude and climate. This study uses a review of the literature on RSV seasonality to investigate whether a global pattern in RSV epidemics can be found. A comparison of morbidity and mortality caused by RSV in developed vs. developing countries is also presented. The seasons in which RSV epidemics occur typically depend on geographic location and altitude. During these seasons the epidemics tend to appear in clusters. Although the appearance pattern of these epidemics varies from one continent to another, they usually begin in coastal areas. RSV is the cause of one-fifth of lower respiratory infections worldwide. Generally RSV mortality is low, with a median value of zero. However, RSV mortality in developing countries is significantly higher than RSV mortality in developed countries.

Low mortality rates related to respiratory virus infections after bone marrow transplantation

Respiratory viruses (RVs) frequently cause severe respiratory disease in bone marrrow transplant (BMT) recipients. To evaluate the frequency of RV, nasal washes were collected year-round from BMT recipients with symptoms of upper respiratory tract infection (URI). Direct immunofluorescence assay was performed for respiratory syncytial virus (RSV), influenza (Flu) A and B, adenovirus and parainfluenza (Paraflu) virus. Patients with RSV pneumonia or with upper RSV infection, but considered at high risk for developing RSV pneumonia received aerosolized ribavirin. Oseltamivir was given to patients with influenza. A total of 179 patients had 392 episodes of URI. In all, 68 (38%) tested positive: RSV was detected in 18 patients (26.4%), Flu B in 17 (25%), Flu A in 11 (16.2%) and Paraflu in 7 (10.3%). A total of 14 patients (20.6%) had multiple RV infections or coinfection. RSV pneumonia developed in 55.5% of the patients with RSV-URI. One of the 15 patients (6.6%) with RSV pneumonia died. Influenza pneumonia was diagnosed in three patients (7.3%). RSV and influenza infections peaked in fall-winter and winter-spring months, respectively. We observed decreased rates of influenza and parainfluenza pneumonia and low mortality because of RSV pneumonia. The role of antiviral interventions such as aerosolized ribavirin and new neuraminidase inhibitors remains to be defined in randomized trials.